Pfizer And BioNTech Are Taking The Next Step Toward A Pan Covid Shot – Investor's Business Daily

BREAKING: Market Rally Finds Support, But New Buys Struggle

IBD Digital Black Friday Offer

IBD Digital Black Friday Offer

Pfizer (PFE) and BioNTech (BNTX) said Thursday they’ve started testing a next-generation Covid shot. But the vaccine stocks creeped higher.
The next-generation Covid vaccine hopes to loop in a part of the immune system called T cells. Researchers have found that T cells recognize parts of the virus that don’t mutate as rapidly as the spike protein, the target of current vaccines. In theory, this would allow the new vaccine to keep up with new variants.
The companies plan to add the updated technology to their already launched updated booster shot, which blocks the BA.4 and BA.5 subvariants of omicron as well as the ancestral strain.
On the stock market today, both vaccine stocks reversed earlier losses. Pfizer stock rose 0.6% to 48.33. BioNTech stock gained 0.8% and closed at 166.26.
The companies said they plan to test the new vaccine in 180 healthy adults age 18-55 in the U.S. Every participant will have received at least three doses of a messenger RNA-based Covid vaccine. Moderna (MRNA) makes the other mRNA shot available in the U.S.
The study will test different dose levels of the new vaccine in combination with the omicron-adapted bivalent booster shot. They hope the new vaccine will generate stronger and longer-term protection. Pfizer and BioNTech say the study is part of their efforts to develop a vaccine that would block every strain of the Covid-causing virus.
Extending the Covid franchise will be important for the vaccine stocks. Analysts expect BioNTech’s sales peaked last year. They forecast Pfizer and Moderna will hit their peaks this year. So far, uptake of the bivalent booster shot is minimal. About 10% of people age 5 and older — the eligible population — have gotten those updated shots.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
Halozyme Gets Under Your Skin To Deliver Blockbuster Drugs And Booming Growth
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
See IBD Stock Lists & Get Pass/Fail Ratings For All Your Stocks With IBD Digital
Options Trading: How To Start Using Options, How To Manage Risk
IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks
11/16/2022 A Relative Strength Rating upgrade for Moderna shows improving technical performance.
11/16/2022 A Relative Strength Rating upgrade for Moderna shows improving technical…
Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!
Get market updates, educational videos, webinars, and stock analysis.
Learn how you can make more money with IBD’s investing tools, top-performing stock lists, and educational content.
Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. Authors may own the stocks they discuss. The information and content are subject to change without notice.
*Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.
Ownership data provided by Refinitiv and Estimates data provided by FactSet.
© 2000-2022 Investor’s Business Daily, LLC. All rights reserved


Leave a Reply

Your email address will not be published. Required fields are marked *